References:

[1]国家卫生健康委.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-19].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdfNATIONALHEALTHCOMMISSION.Thenewcoronaviruspneumoniadiagnosisandtreatmentplan(Trialversion6).[EB/OL].(2020-02-18[2020-02-19].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
[2] HASKELBERG H, MALLON P W, HOY J, et al. Bonemineral density over 96 weeks in adults failing first - linetherapy randomized to raltegravir/ lopinavir/ ritonavir compared with standard second - line therapy[ J] . J AcquirImmune Defic Syndr, 2014,67( 2) :161 -168.
[3] PAO V Y, LEE G A, TAYLOR S, et al. The protease inhibitor combination lopinavir/ ritonavir does not decrease insulin secretion in healthy, HIV - seronegative volunteers [ J] . AIDS, 2010, 24( 2) :265 -270.
[4] WEGZYN C M, FREDRICK L M, STUBBS R O, et al.Diarrhea Associated with lopinavir/ ritonavir - based therapy: results of a Meta - Analysis of 1469 HIV -1 - Infected Participants[ J] . J Int Assoc Phys AIDS Care, 2012,11( 4) :252 -259.
[5] DAI L, LIU A, ZHANG H, et al. Impact of lopinavir/ritonavir and efavirenz - based antiretroviral therapy on the lipid profile of Chinese HIV/ AIDS treatment - naive patients in Beijing: a retrospective study[ J] . Int J Antimicrob Agents, 2019, 17( 5) : 324 -334.
[6]陈岷,童荣生,边原,等.皮下注射α-干扰素治疗2019年新型冠状病毒的循证快速评估[J/OL].医药导报:1-19[2020-02-29].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.
[7]刘松松,谢益鸣.101例藿香正气水药品不良反应文献分析[J].中国药物警戒,2017,14(5):317-320.
[8]黄玲,王艳,吴曙粤.中药麻黄药理作用研究进展[J].中外医疗,2018,37(7):195-198.
[9] Clinical characteristics of 2019 novel coronavirus infection in China, MedRxiv. https: / / www. medrxiv. org/ content/10. 1101/2020. 02. 06. 20020974v1
[10]顾植山.五运六气看当前新型冠状病毒肺炎疫情[J/OL].世界中医药:1-6[2020-02-29].http://kns.cnki.net/kcms/detail/11.5529.R.20200222.2028.004.html.
[11] Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China, Preprint in MedRXiv. https: / / www. medrxiv. org/ content/10. 1101/2020. 02.10. 20021675v1
[12]李广兴,潘龙.冠状病毒基因组结构和相关蛋白研究进展[J].东北农业大学学报,2013,44(9):149-154.
[13] XU X, CHEN P, WANG J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[ J] .Sci China Life Sci, 2020, doi: org/10. 1007/ s11427 -020 -1637 -5.
[14]杨家耀,苏文,乔杰,等.90例普通型新型冠状病毒肺炎患者中医证候与体质分析[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200221.1513.004.html.
[15]孙宏源,毕颖斐,朱振刚,等.天津地区88例新型冠状病毒肺炎患者中医证候特征初探[J/OL].中医杂志:1-4[2020-02-29].http://kns.cnki.net/kcms/detail/11.2166.R.20200224.0948.004.html.
[16]张佳乐,杨莉,鲜天才,等.艾灸防控新型冠状病毒肺炎的思路探讨[J/OL].医学争鸣:1-9[2020-02-29].http://kns.cnki.net/kcms/detail/61.1481.r.20200227.1909.002.html.
[17]中国针灸学会.关于印发《新型冠状病毒肺炎针灸干预的指导意见(第一版)》的通知[EB/OL].(2020-02-09)[2020-02-09].http://www.caam.cn/articl/2183.
[18]吕沛宛,王赛男,唐祖宣.艾灸早期介入防治新型冠状病毒肺炎可行性分析[J].中医学报.http://kns.cnki.net/kcms/detail/41.1411.r.20200219.0940.002.html.
[19]赵鸿,王宇红,奉延旗,等.中药香囊芳香气味空气消毒的效果观察[J].中国中医药现代远程教育,2013,11(14):157-158.
[20] Wang H, Zhang Q, Cheng M L, et al. Effect of the MiaoYao Fanggan Sachet - derived isorhamnetin on TLR2/4 and NKp46 expression in mice. Journal of Ethnopharmacology,2012,144( 1) :138 -144.
[21]吕鹏,白明学.中药香囊芳香气味空气消毒的效果探讨[J].海峡药学,2017,29(2):47-48.
[22]姚伟,赵向东,冯全生.古代芳香药物在疫病预防中的运用[J].国医论坛,2011,26(5):47-49.
[23]牛明,王睿林,王仲霞,等.基于临床经验和分子对接技术的抗新型冠状病毒中医组方快速筛选模式及应用[J/OL].中国中药杂志:1-8[2020-02-29].https://doi.org/10.19540/j.cnki.cjcmm.20200206.501.[1]国家卫生健康委.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-19].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdfNATIONALHEALTHCOMMISSION.Thenewcoronaviruspneumoniadiagnosisandtreatmentplan(Trialversion6).[EB/OL].(2020-02-18[2020-02-19].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
[2] HASKELBERG H, MALLON P W, HOY J, et al. Bonemineral density over 96 weeks in adults failing first - linetherapy randomized to raltegravir/ lopinavir/ ritonavir compared with standard second - line therapy[ J] . J AcquirImmune Defic Syndr, 2014,67( 2) :161 -168.
[3] PAO V Y, LEE G A, TAYLOR S, et al. The protease inhibitor combination lopinavir/ ritonavir does not decrease insulin secretion in healthy, HIV - seronegative volunteers [ J] . AIDS, 2010, 24( 2) :265 -270.
[4] WEGZYN C M, FREDRICK L M, STUBBS R O, et al.Diarrhea Associated with lopinavir/ ritonavir - based therapy: results of a Meta - Analysis of 1469 HIV -1 - Infected Participants[ J] . J Int Assoc Phys AIDS Care, 2012,11( 4) :252 -259.
[5] DAI L, LIU A, ZHANG H, et al. Impact of lopinavir/ritonavir and efavirenz - based antiretroviral therapy on the lipid profile of Chinese HIV/ AIDS treatment - naive patients in Beijing: a retrospective study[ J] . Int J Antimicrob Agents, 2019, 17( 5) : 324 -334.
[6]陈岷,童荣生,边原,等.皮下注射α-干扰素治疗2019年新型冠状病毒的循证快速评估[J/OL].医药导报:1-19[2020-02-29].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.
[7]刘松松,谢益鸣.101例藿香正气水药品不良反应文献分析[J].中国药物警戒,2017,14(5):317-320.
[8]黄玲,王艳,吴曙粤.中药麻黄药理作用研究进展[J].中外医疗,2018,37(7):195-198.
[9] Clinical characteristics of 2019 novel coronavirus infection in China, MedRxiv. https: / / www. medrxiv. org/ content/10. 1101/2020. 02. 06. 20020974v1
[10]顾植山.五运六气看当前新型冠状病毒肺炎疫情[J/OL].世界中医药:1-6[2020-02-29].http://kns.cnki.net/kcms/detail/11.5529.R.20200222.2028.004.html.
[11] Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China, Preprint in MedRXiv. https: / / www. medrxiv. org/ content/10. 1101/2020. 02.10. 20021675v1
[12]李广兴,潘龙.冠状病毒基因组结构和相关蛋白研究进展[J].东北农业大学学报,2013,44(9):149-154.
[13] XU X, CHEN P, WANG J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[ J] .Sci China Life Sci, 2020, doi: org/10. 1007/ s11427 -020 -1637 -5.
[14]杨家耀,苏文,乔杰,等.90例普通型新型冠状病毒肺炎患者中医证候与体质分析[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200221.1513.004.html.
[15]孙宏源,毕颖斐,朱振刚,等.天津地区88例新型冠状病毒肺炎患者中医证候特征初探[J/OL].中医杂志:1-4[2020-02-29].http://kns.cnki.net/kcms/detail/11.2166.R.20200224.0948.004.html.
[16]张佳乐,杨莉,鲜天才,等.艾灸防控新型冠状病毒肺炎的思路探讨[J/OL].医学争鸣:1-9[2020-02-29].http://kns.cnki.net/kcms/detail/61.1481.r.20200227.1909.002.html.
[17]中国针灸学会.关于印发《新型冠状病毒肺炎针灸干预的指导意见(第一版)》的通知[EB/OL].(2020-02-09)[2020-02-09].http://www.caam.cn/articl/2183.
[18]吕沛宛,王赛男,唐祖宣.艾灸早期介入防治新型冠状病毒肺炎可行性分析[J].中医学报.http://kns.cnki.net/kcms/detail/41.1411.r.20200219.0940.002.html.
[19]赵鸿,王宇红,奉延旗,等.中药香囊芳香气味空气消毒的效果观察[J].中国中医药现代远程教育,2013,11(14):157-158.
[20] Wang H, Zhang Q, Cheng M L, et al. Effect of the MiaoYao Fanggan Sachet - derived isorhamnetin on TLR2/4 and NKp46 expression in mice. Journal of Ethnopharmacology,2012,144( 1) :138 -144.
[21]吕鹏,白明学.中药香囊芳香气味空气消毒的效果探讨[J].海峡药学,2017,29(2):47-48.
[22]姚伟,赵向东,冯全生.古代芳香药物在疫病预防中的运用[J].国医论坛,2011,26(5):47-49.
[23]牛明,王睿林,王仲霞,等.基于临床经验和分子对接技术的抗新型冠状病毒中医组方快速筛选模式及应用[J/OL].中国中药杂志:1-8[2020-02-29].https://doi.org/10.19540/j.cnki.cjcmm.20200206.501.